

Kenneth A. Clark

PARTNER

Corporate
Palo Alto
San Diego

kclark@wsgr.com
650-320-4742



FOCUS AREAS

Biotech
Capital Markets
Corporate
Corporate Governance
Life Sciences
Technology Transactions

HIGHLIGHTS

- **Experienced Legal Advisor to Biotech Companies**
Ken acts as outside general counsel to biotechnology companies and their boards of directors.
- **Substantial Transactions Experience**
Ken has negotiated more than 100 major strategic alliance and M&A transactions. In addition to partnering agreements and strategic transactions, Ken represents companies in financings, spin-outs, and other deals.
- **A Recognized Practitioner**
Ken has been recognized in *Chambers USA* as one of the top biotechnology attorneys in the U.S.

EXPERIENCE

Ken Clark serves as general counsel to companies and their boards of directors, primarily in the biotechnology industry. Ken has extensive expertise in partnering and strategic transactions, having negotiated more than 100 major strategic alliance and M&A transactions. He also regularly represents companies in financings, spin-outs, and related matters.

Ken served on the firm's board of directors from 2011 to 2014 and from 2002 to 2006, and previously was a member of the firm's Policy Committee. Ken served as a director of Pharmacyclics, Inc. (NASDAQ: PCYC) from 2012 until their sale to AbbVie in 2015.

CREDENTIALS

Education

- J.D., University of Texas School of Law
Order of Coif; Chancellor's Order; Articles Editor, Texas Law Review
- B.A., Vanderbilt University
Magna Cum Laude, Phi Beta Kappa

Admissions

- State Bar of California

MATTERS

Select Transactions

- Affymax/Nektar Therapeutics

- Alector/AbbVie
- Alector/GSK
- Alector/Innovent
- Amicus/GSK
- Amicus/Shire Pharmaceuticals
- Amgen/Xencor
- Amgen/GSK
- Aragon/Johnson & Johnson
- Array/Amgen
- Array/Novartis
- Calistoga Pharmaceuticals/Gilead
- Cell Genesys/Hoescht
- Cell Genesys/Japan Tobacco, Inc.
- Cytokinetics/Amgen
- Cytokinetics/GlaxoSmithKline
- CytomX/BMS
- CytomX/Pfizer
- Denali Therapeutics/Takeda
- Dren/Pfizer
- Genentech/Biogen
- Genta/Aventis
- IGM/Sanofi
- Inviragen/Takeda
- Lyell/GSK collaboration
- Macusight/Santen
- Maverick Therapeutics/Takeda
- Nanjing Legend Biotech/Janssen
- ParAllele/Affymetrix
- Peloton Therapeutics/Merck
- Pharmacyclics/Janssen Biotech
- Pharmacyclics/AbbVie
- QanticeI/Celgene
- Rinat/Pfizer
- SARCode/Shire
- Sequentia/Adaptive Biotechnologies
- Seragon/Genentech
- Stromedix/Biogen
- Sunesis Pharmaceuticals/Biogen
- Synthekine/Merck
- Taiho Pharmaceutical Co. Ltd./Merck
- Taiho Pharmaceutical Co. Ltd./Servier
- Taiho Pharmaceutical Co. Ltd./Helsinn SA
- Taiho Pharmaceutical Co. Ltd./American Bioscience
- Taiho Pharmaceutical Co. Ltd./Sanofi Aventis
- Taiho Pharmaceutical Co. Ltd./Arcus Bioscience
- Tercica/Genentech
- VentiRx/Celgene
- Vividion/Roche
- Vivus/Astra
- XenoPort/Astellas Pharma, Inc.
- XenoPort/GlaxoSmithKline